The Historical Progression of Positron Emission Tomography Research in Neuroendocrinology
J Bini - Frontiers in Neuroendocrinology, 2023 - Elsevier
The rapid and continual development of a number of radiopharmaceuticals targeting
different receptor, enzyme and small molecule systems has fostered Positron Emission …
different receptor, enzyme and small molecule systems has fostered Positron Emission …
[HTML][HTML] Arginine Vasopressin, Synaptic Plasticity, and Brain Networks
AB Marcinkowska, VC Biancardi… - Current …, 2022 - ncbi.nlm.nih.gov
The arginine vasopressin (AVP), a neurohypophysial hormone, is synthesized within
specific sites of the central nervous system and axonally transported to multiple areas, acting …
specific sites of the central nervous system and axonally transported to multiple areas, acting …
[HTML][HTML] Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist
GM Castillo, Y Yao, RE Guerra, H Jiang… - Biomedicine & …, 2024 - Elsevier
Cirrhosis is a liver disease that leads to increased intrahepatic resistance, portal
hypertension (PH), and splanchnic hyperemia resulting in ascites, variceal bleeding, and …
hypertension (PH), and splanchnic hyperemia resulting in ascites, variceal bleeding, and …
Feasibility Study to Assess Canagliflozin Distribution and Sodium‐Glucose Co‐Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes
S van Der Hoek, ATM Willemsen… - Clinical …, 2023 - Wiley Online Library
Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors, including canagliflozin, reduce the risk
of cardiovascular and kidney outcomes in patients with and without type 2 diabetes, albeit …
of cardiovascular and kidney outcomes in patients with and without type 2 diabetes, albeit …
Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [11C]Telmisartan
S van der Hoek, DJ Mulder… - Clinical …, 2022 - Wiley Online Library
The angiotensin receptor blocker telmisartan slows progression of kidney disease in
patients with type 2 diabetes (T2D), yet many patients remain at high risk for progressive …
patients with type 2 diabetes (T2D), yet many patients remain at high risk for progressive …
[HTML][HTML] Effect of scan-time shortening on the 11C-PHNO binding potential to dopamine D3 receptor in humans and test–retest reliability
K Matsunaga, M Tonomura, K Abe… - Annals of Nuclear …, 2023 - Springer
Objective 11C-PHNO is a PET radioligand most specific to dopamine D3 receptor (D3R).
The long scan duration of 120 min used in quantification of 11C-PHNO binding to D3R in …
The long scan duration of 120 min used in quantification of 11C-PHNO binding to D3R in …
[CITATION][C] Effect of scan‑time shortening on the 11C‑PHNO binding potential to dopamine D
K Matsunaga, M Tonomura, K Abe, E Shimosegawa - 2023